Angioimmunoblastic T-cell lymphoma
MONDO:0004977A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes and extranodal sites. The clinical course is typically aggressive.
Also known as: AILD, AILT, T-cell lymphoma, AILD type, angioimmunoblastic T-cell lymphoma, angioimmunoblastic lymphadenopathy, angioimmunoblastic lymphadenopathy type T-cell lymphoma, angioimmunoblastic lymphadenopathy with Dysproteinemia, immunoblastic lymphadenopathy
1986 clinical trials for this condition and its sub-types, 58 tagged with Angioimmunoblastic T-cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Supercharged immune cells take on tough T-Cell cancers
Disease control Not yet recruitingThis Phase 2 trial tests a new treatment for aggressive T-cell blood cancers. Patients receive specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, to try to keep the cancer in remission. The study will enroll 70 adults aged 18-80 whose…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug cocktails aim to outsmart Hard-to-Treat T-Cell lymphomas
Disease control Not yet recruitingThis early-phase trial tests two different drug combinations for people with T-cell lymphoma that has come back or not responded to prior treatment. One group receives belinostat plus azacitidine; the other receives belinostat plus pralatrexate. The goal is to find the safest dos…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New vaccine aims to fight Hard-to-Treat EBV cancers
Disease control Not yet recruitingThis study tests a vaccine called KSD-101 in 80 people with blood cancers linked to the Epstein-Barr virus (EBV). The vaccine uses a patient's own immune cells to target EBV and cancer. Researchers want to see if it can shrink tumors or keep the disease from coming back.
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for hard-to-treat lymphoma: experimental drug enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug called BR101801 in 44 people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not responded to standard treatments. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive the dru…
Phase 2 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC